MedTrace Logo

Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

NCT00307528 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2019-10-30

No results posted yet for this study

Summary

As the licensed Pneumovax 23™ vaccine is not always satisfactory in elderly subjects, the safety and the immune response of the new investigational pneumococcal protein vaccine is evaluated in healthy elderly population.

Conditions

  • Prophylaxis Invasive Pneumococcal Diseases and Pneumonia

Interventions

BIOLOGICAL

Pneumococcal vaccine GSK513026

Two-dose intramuscular injection. Five different formulations, each administered to one Group

BIOLOGICAL

Pneumovax 23™

Single dose intramuscular injection.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-20
Primary Completion
2005-03-30
Completion
2005-03-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307528 on ClinicalTrials.gov